Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism

Figure 6 Effect of saroglitazar on hepatic steatosis and lipid accumulation in therapeutic study design. A: Liver histology was evaluated using hematoxylin and eosin staining to assess the degree of steatosis. ^bP < 0.01, ^cP < 0.001; B and C: Liver tissue samples were homogenized to quantify hepatic triglyceride and total cholesterol levels. Data are presented as mean ± SEM (n = 8 for normal control and n = 9 disease control and treatments). Statistical analysis was performed using oneway analysis of variance followed by Dunnett’s multiple comparison test. ^bP < 0.01 vs disease control group. HE: Hematoxylin and eosin; PO: Orally; OD: Once daily; BID: Twice daily; UDCA: Ursodeoxycholic acid.